SCHEMBL1004589

SCHEMBL1004589

CN(c1ncccn1)S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.54
CYP2C8 P10632 2/20 0.54
CYP2C18 P33260 2/20 0.54
TSHR P16473 3/20 0.49
LMNA P02545 2/20 0.49
AURKA O14965 1/20 0.49
DHFR P00374 1/20 0.49
C1R P00736 1/20 0.48
PRSS1 P07477 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CA12 O43570 2/20 0.45
CA9 Q16790 2/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14507082 0.83 NR1I2 (0.51) CYP2C9CYP2C18C1RCYP2C19CA12
Sulfadiazine, Silver SCHEMBL16043898 0.79 TSHR (0.49) CYP2C9CYP2C8CYP2C18TSHRLMNA
SCHEMBL31220001 0.78 CYP2C9 (0.56) CYP2C9CYP2C8CYP2C18TSHRLMNA
SCHEMBL26488037 0.78 TDP1 (0.53) CYP2C9CYP2C8CYP2C18TSHRLMNA
SCHEMBL5121845 0.77 MAPT (0.68) CYP2C9CYP2C8CYP2C18TSHRLMNA
SCHEMBL18560169 0.77 CYP2C9 (0.46) CYP2C9CYP2C8CYP2C18TSHRLMNA
SCHEMBL2518894 0.76 CA12 (0.71) CYP2C9CYP2C8CYP2C18TSHRLMNA
SCHEMBL519624 0.74 LMNA (0.59) CYP2C9TSHRLMNAPKMCA12
SCHEMBL5121853 0.74 C5AR1 (0.59) CYP2C9CYP2C8CYP2C18TSHRLMNA
SCHEMBL31219708 0.73 TSHR (0.44) CYP2C9CYP2C8CYP2C18TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070141096-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. 2007-06-21 US claimed
EP-1119345-A4 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GEN MILLS INC (US) 2004-06-16 EP claimed
US-20020044968-A1 High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion GENERAL MILLS, INC. 2002-04-18 US claimed
JP-2002511777-A 2002-04-16 JP claimed
EP-1119345-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. (US) 2001-08-01 EP claimed
WO-2000021504-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. (US) 2000-04-20 WO claimed
EP-0935523-A4 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GEN MILLS INC (US) 1999-12-29 EP claimed
EP-0935523-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GENERAL MILLS, INC. (US) 1999-08-18 EP claimed
WO-1998018610-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES LENGERICH BERNHARD H VAN (US) 1998-05-07 WO claimed
EP-0358105-B1 Method and apparatus of continuously manufacturing solid pharmaceutical forms BASF AG (DE) 1994-03-02 EP claimed
EP-0240904-B1 PROCESS FOR THE PREPARATION OF SOLID PHARMACEUTICAL FORMS BASF Aktiengesellschaft (DE) 1992-07-01 EP claimed
US-5073379-A Melts, extrusion, rolling. tablets BASF AKTIENGESELLSCHAFT (DE) 1991-12-17 US claimed
EP-0358107-A2 Process for the preparation of pharmaceutical tablets BASF Aktiengesellschaft (DE) 1990-03-14 EP claimed
EP-0358105-A2 Method and apparatus of continuously manufacturing solid pharmaceutical forms BASF Aktiengesellschaft (DE) 1990-03-14 EP claimed
US-4801460-A N-VINYLPYRROLIDONE POLYMER BINDER BASF AKTIENGESELLSCHAFT (DE) 1989-01-31 US claimed
EP-0240904-A2 Process for the preparation of solid pharmaceutical forms BASF Aktiengesellschaft (DE) 1987-10-14 EP claimed
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 EP disclosed
WO-2024238574-A1 CDK INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2024-11-21 WO disclosed
US-4801460-A N-VINYLPYRROLIDONE POLYMER BINDER BASF AKTIENGESELLSCHAFT (DE) 1989-01-31 US disclosed
EP-0240904-A2 Process for the preparation of solid pharmaceutical forms BASF Aktiengesellschaft (DE) 1987-10-14 EP disclosed